Virus World
378.2K views | +117 today
Follow
Virus World
Virus World provides a daily blog of the latest news in the Virology field and the COVID-19 pandemic. News on new antiviral drugs, vaccines, diagnostic tests, viral outbreaks, novel viruses and milestone discoveries are curated by expert virologists. Highlighted news include trending and most cited scientific articles in these fields with links to the original publications. Stay up-to-date with the most exciting discoveries in the virus world and the last therapies for COVID-19 without spending hours browsing news and scientific publications. Additional comments by experts on the topics are available in Linkedin (https://www.linkedin.com/in/juanlama/detail/recent-activity/)
Curated by Juan Lama
Your new post is loading...
Scooped by Juan Lama
Scoop.it!

Reduced Neutralizing Activity of post-SARS-CoV-2 Vaccination Serum Against Variants B.1.617.2, B.1.351, B.1.1.7+E484K and a Sub-Variant of C.37 | medRxiv

Reduced Neutralizing Activity of post-SARS-CoV-2 Vaccination Serum Against Variants B.1.617.2, B.1.351, B.1.1.7+E484K and a Sub-Variant of C.37 | medRxiv | Virus World | Scoop.it

Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning. Several of these viral variants have the potential to partially escape neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that mimics physiological conditions.

 

We found only small decreases in neutralization against B.1.526 and an intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America and was detected in Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity.

 

Preprint Available in medRxiV (July 23, 2021):

https://doi.org/10.1101/2021.07.21.21260961 

No comment yet.
Scooped by Juan Lama
Scoop.it!

In Oregon, Scientists Find a Virus Variant With a Worrying Mutation - The New York Times

In Oregon, Scientists Find a Virus Variant With a Worrying Mutation - The New York Times | Virus World | Scoop.it

In a single sample, geneticists discovered a version of the coronavirus first identified in Britain with a mutation originally reported in South Africa.  Scientists in Oregon have spotted a homegrown version of a fast-spreading variant of the coronavirus that first surfaced in Britain — but now combined with a mutation that may make the variant less susceptible to vaccines. The researchers have so far found just a single case of this formidable combination, but genetic analysis suggested that the variant had been acquired in the community and did not arise in the patient. “We didn’t import this from elsewhere in the world — it occurred spontaneously,” said Brian O’Roak, a geneticist at Oregon Health and Science University who led the work. He and his colleagues participate in the Centers for Disease Control and Prevention’s effort to track variants, and they have deposited their results in databases shared by scientists. The variant originally identified in Britain, called B.1.1.7, has been spreading rapidly across the United States, and accounts for at least 2,500 cases in 46 states. This form of the virus is both more contagious, and more deadly, than the original version, and is expected to account for most infections in America in a few weeks. The new version that surfaced in Oregon has the same backbone, but also a mutation — E484K, or “Eek” — seen in variants of the virus circulating in South Africa, Brazil and New York City.

 

Lab studies and clinical trials in South Africa indicate that the Eek mutation renders the current vaccines less effective by blunting the body’s immune response. (The vaccines still work, but the findings are worrying enough that Pfizer-BioNTech and Moderna have begun testing new versions of their vaccines designed to defeat the variant found in South Africa.) The B.1.1.7 variant with Eek also has emerged in Britain, designated as a “variant of concern” by scientists. But the virus identified in Oregon seems to have evolved independently, Dr. O’Roak said. Dr. O’Roak and his colleagues found the variant among coronavirus samples collected by the Oregon State Public Health Lab across the state, including some from an outbreak in a health care setting. Of the 13 test results they analyzed, 10 turned out to be B.1.1.7 alone, and one the combination. Other experts said the discovery was not surprising, because the Eek mutation has arisen in forms of the virus all over the world. But the mutation’s occurrence in B.1.1.7 is worth watching, they said. In Britain, this version of the variant accounts for a small number of cases. But by the time the combination evolved there, B.1.1.7 had already spread through the country.

 

“We’re at the point where B.1.1.7 is just being introduced” into the United States, said Stacia Wyman, an expert in computational genomics at the University of California, Berkeley. “As it evolves, and as it slowly becomes the dominant thing, it could accumulate more mutations.” Viral mutations may enhance or weaken one another. For example, the variants identified in South Africa and Brazil contain many of the same mutations, including Eek. But the Brazilian version has a mutation, K417N, that is not present in the version from South Africa.  In a study published Thursday in Nature, researchers compared antibody responses to all three variants of concern — the ones identified in Britain, South Africa and Brazil. Consistent with other studies, they found that the variant that pummeled South Africa is most resistant to antibodies produced by the immune system. But the variant circulating in Brazil was not as resistant, even though it carried the Eek mutation. “If you have the second mutation, you don’t see as bad an effect,” said Michael Diamond, a viral immunologist at Washington University in St. Louis, who led the study. It’s too early to say whether the variant in Oregon will behave like the ones in South Africa or Brazil. But the idea that other mutations could weaken Eek’s effect is “excellent news,” Dr. Wyman said. Over all, she said, the Oregon finding reinforces the need for people to continue to take precautions, like wearing a mask, until a substantial portion of the population is immunized. “People need to not freak out but to continue to be vigilant,” she said. “We can’t let down our guard yet while there’s still these more transmissible variants circulating.”

No comment yet.